CRISPR causes serious DNA damage with high frequency – but it’s often overlooked
By Claire Robinson,
GMWatch
| 08. 09. 2023
The latest in a long series of papers has been published, detailing unintended effects of CRISPR gene editing. The new review summarises the many types of serious unintended on-target (at the intended edit site) DNA damage resulting from CRISPR/Cas gene editing.
The review appears as the European Commission and the UK government maintain their pretence that gene editing is a precise, predictable, and controllable technique and that food plants made with this technology are therefore as safe as those produced by conventional breeding.
The authors of the new paper, from Rice University in the US, reviewed the literature on CRISPR gene editing in human, primate, and mouse cells. They found that CRISPR-induced double-strand breaks in the DNA caused numerous large unintended on-target genetic damages, including large and small deletions and insertions, and chromosomal rearrangements of genetic material. And they note that even large on-target gene modifications are not detectable by standard methods.
Because the unintended effects of CRISPR gene editing highlighted in the new review are on-target mutations at the intended edit site, improving the targeting of the editing tool...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...